Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 20 | 2026 | 263 | 4.800 |
Why?
|
| Microbiota | 12 | 2025 | 169 | 3.260 |
Why?
|
| Clostridium Infections | 4 | 2025 | 49 | 1.820 |
Why?
|
| Anti-Bacterial Agents | 11 | 2025 | 806 | 1.770 |
Why?
|
| Enterobacteriaceae | 3 | 2024 | 19 | 1.660 |
Why?
|
| Dysbiosis | 6 | 2022 | 74 | 1.600 |
Why?
|
| Bacteriocins | 3 | 2025 | 23 | 1.250 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 29 | 0.870 |
Why?
|
| Succinic Acid | 1 | 2024 | 11 | 0.870 |
Why?
|
| Inflammation | 3 | 2021 | 1193 | 0.860 |
Why?
|
| Hyperplasia | 1 | 2024 | 91 | 0.850 |
Why?
|
| Models, Theoretical | 2 | 2016 | 274 | 0.790 |
Why?
|
| Microbial Consortia | 2 | 2025 | 11 | 0.770 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 66 | 0.760 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2020 | 73 | 0.730 |
Why?
|
| Fecal Microbiota Transplantation | 4 | 2025 | 20 | 0.700 |
Why?
|
| Bacteria | 7 | 2026 | 336 | 0.680 |
Why?
|
| Escherichia coli Infections | 1 | 2022 | 90 | 0.670 |
Why?
|
| Tuberculosis | 2 | 2021 | 312 | 0.620 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 60 | 0.590 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2018 | 221 | 0.580 |
Why?
|
| Microbial Interactions | 1 | 2017 | 5 | 0.540 |
Why?
|
| Tetrathionic Acid | 1 | 2017 | 2 | 0.530 |
Why?
|
| Antibiosis | 1 | 2017 | 8 | 0.530 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2017 | 22 | 0.530 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 170 | 0.520 |
Why?
|
| Nursing Homes | 4 | 2022 | 686 | 0.510 |
Why?
|
| Salmonella | 1 | 2017 | 45 | 0.510 |
Why?
|
| Probiotics | 1 | 2017 | 57 | 0.500 |
Why?
|
| Genetic Engineering | 1 | 2017 | 114 | 0.490 |
Why?
|
| Bacteriophages | 1 | 2017 | 65 | 0.480 |
Why?
|
| Biofilms | 1 | 2017 | 85 | 0.480 |
Why?
|
| Biota | 1 | 2014 | 3 | 0.420 |
Why?
|
| Frailty | 3 | 2022 | 131 | 0.420 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 279 | 0.400 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2025 | 206 | 0.400 |
Why?
|
| Peptides | 1 | 2017 | 590 | 0.390 |
Why?
|
| Feces | 6 | 2025 | 118 | 0.380 |
Why?
|
| Urinary Tract Infections | 2 | 2025 | 97 | 0.380 |
Why?
|
| Mice | 8 | 2024 | 11137 | 0.370 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 187 | 0.360 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2024 | 97 | 0.330 |
Why?
|
| Escherichia coli | 3 | 2025 | 714 | 0.310 |
Why?
|
| Humans | 26 | 2026 | 65462 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2024 | 353 | 0.290 |
Why?
|
| Antitubercular Agents | 2 | 2021 | 84 | 0.280 |
Why?
|
| Animals | 8 | 2024 | 21380 | 0.270 |
Why?
|
| Alzheimer Disease | 2 | 2026 | 766 | 0.230 |
Why?
|
| Klebsiella pneumoniae | 2 | 2025 | 29 | 0.230 |
Why?
|
| Intestinal Mucosa | 4 | 2023 | 250 | 0.230 |
Why?
|
| Computer Simulation | 2 | 2018 | 485 | 0.220 |
Why?
|
| Urine | 1 | 2025 | 47 | 0.220 |
Why?
|
| Plant Diseases | 1 | 2024 | 11 | 0.220 |
Why?
|
| Immunity, Innate | 2 | 2023 | 827 | 0.220 |
Why?
|
| Gram-Negative Bacteria | 1 | 2024 | 56 | 0.210 |
Why?
|
| Budesonide | 1 | 2024 | 22 | 0.210 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 183 | 0.200 |
Why?
|
| Colitis, Ulcerative | 1 | 2024 | 76 | 0.200 |
Why?
|
| Feeding Methods | 1 | 2023 | 11 | 0.200 |
Why?
|
| Colon | 1 | 2024 | 147 | 0.200 |
Why?
|
| Aged | 8 | 2026 | 15051 | 0.200 |
Why?
|
| Algorithms | 2 | 2021 | 1050 | 0.190 |
Why?
|
| Metagenomics | 3 | 2022 | 29 | 0.190 |
Why?
|
| Plasma Cells | 1 | 2023 | 52 | 0.190 |
Why?
|
| Female | 14 | 2026 | 34193 | 0.180 |
Why?
|
| Male | 13 | 2026 | 31186 | 0.180 |
Why?
|
| Cognition | 1 | 2026 | 510 | 0.180 |
Why?
|
| Carbapenems | 1 | 2022 | 8 | 0.180 |
Why?
|
| Cognitive Dysfunction | 1 | 2026 | 350 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2026 | 5643 | 0.170 |
Why?
|
| Bacterial Load | 1 | 2021 | 30 | 0.170 |
Why?
|
| Biodiversity | 1 | 2021 | 49 | 0.160 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 47 | 0.160 |
Why?
|
| Cytokines | 1 | 2024 | 951 | 0.160 |
Why?
|
| Hospitals | 1 | 2023 | 397 | 0.160 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 110 | 0.160 |
Why?
|
| Mice, Knockout | 1 | 2024 | 2162 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2021 | 2632 | 0.150 |
Why?
|
| Middle Aged | 8 | 2026 | 18386 | 0.150 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 405 | 0.150 |
Why?
|
| Listeriosis | 1 | 2019 | 29 | 0.140 |
Why?
|
| Mucosal-Associated Invariant T Cells | 1 | 2018 | 2 | 0.140 |
Why?
|
| Lymphocyte Activation | 2 | 2018 | 753 | 0.140 |
Why?
|
| Symbiosis | 1 | 2019 | 36 | 0.140 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2018 | 8 | 0.140 |
Why?
|
| Disk Diffusion Antimicrobial Tests | 1 | 2017 | 2 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2019 | 150 | 0.130 |
Why?
|
| Gene Order | 1 | 2017 | 33 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1143 | 0.130 |
Why?
|
| Diffusion | 1 | 2017 | 82 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3488 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2018 | 422 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2017 | 101 | 0.130 |
Why?
|
| Adult | 7 | 2025 | 17460 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2022 | 105 | 0.130 |
Why?
|
| Plasmids | 1 | 2017 | 294 | 0.120 |
Why?
|
| Prevalence | 1 | 2021 | 1451 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1710 | 0.120 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2017 | 123 | 0.120 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2015 | 8 | 0.120 |
Why?
|
| Models, Biological | 1 | 2021 | 1192 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 367 | 0.110 |
Why?
|
| Soft Tissue Infections | 1 | 2015 | 48 | 0.110 |
Why?
|
| Neoplasms | 1 | 2025 | 1372 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 676 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 1631 | 0.100 |
Why?
|
| Emergency Service, Hospital | 2 | 2025 | 1161 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2026 | 89 | 0.090 |
Why?
|
| Healthy Volunteers | 2 | 2022 | 72 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 708 | 0.080 |
Why?
|
| Intestines | 2 | 2023 | 182 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2024 | 1021 | 0.080 |
Why?
|
| Machine Learning | 2 | 2022 | 195 | 0.070 |
Why?
|
| Epithelial Cells | 2 | 2023 | 413 | 0.070 |
Why?
|
| Immunity, Mucosal | 2 | 2018 | 53 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2019 | 3325 | 0.060 |
Why?
|
| Child | 3 | 2024 | 4623 | 0.060 |
Why?
|
| Bacteriuria | 1 | 2025 | 16 | 0.060 |
Why?
|
| Urinalysis | 1 | 2025 | 37 | 0.060 |
Why?
|
| Bile Acids and Salts | 1 | 2025 | 25 | 0.050 |
Why?
|
| Donor Selection | 1 | 2024 | 15 | 0.050 |
Why?
|
| Fluoroquinolones | 1 | 2024 | 33 | 0.050 |
Why?
|
| Parturition | 1 | 2023 | 54 | 0.050 |
Why?
|
| Recurrence | 1 | 2025 | 662 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2024 | 168 | 0.050 |
Why?
|
| Cholesterol, Dietary | 1 | 2023 | 29 | 0.050 |
Why?
|
| Computational Biology | 1 | 2025 | 368 | 0.050 |
Why?
|
| Biological Availability | 1 | 2023 | 210 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 743 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 102 | 0.040 |
Why?
|
| Prebiotics | 1 | 2022 | 18 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2023 | 138 | 0.040 |
Why?
|
| Prognosis | 1 | 2025 | 1789 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 47 | 0.040 |
Why?
|
| Integrin alpha Chains | 1 | 2019 | 11 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 2019 | 33 | 0.040 |
Why?
|
| Software | 1 | 2022 | 401 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2018 | 51 | 0.040 |
Why?
|
| Disease Resistance | 1 | 2018 | 27 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 64 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 203 | 0.030 |
Why?
|
| Infant | 1 | 2023 | 1703 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 536 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 142 | 0.030 |
Why?
|
| Haiti | 1 | 2017 | 15 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 342 | 0.030 |
Why?
|
| Adolescent | 2 | 2018 | 6332 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2019 | 574 | 0.030 |
Why?
|
| Homeostasis | 1 | 2019 | 380 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 463 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2391 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2019 | 531 | 0.030 |
Why?
|
| Dementia | 1 | 2019 | 280 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 1567 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1284 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 2067 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 5806 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2015 | 310 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 995 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1592 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 741 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2721 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 4836 | 0.020 |
Why?
|